Medpace Holdings, Inc. (NASDAQ:MEDP) Holdings Decreased by Sei Investments Co.

Sei Investments Co. cut its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 6.4% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 126,972 shares of the company’s stock after selling 8,677 shares during the quarter. Sei Investments Co.’s holdings in Medpace were worth $52,293,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in MEDP. Rise Advisors LLC acquired a new position in shares of Medpace in the 1st quarter valued at about $27,000. Mather Group LLC. acquired a new position in Medpace in the first quarter valued at approximately $28,000. Fidelis Capital Partners LLC bought a new position in shares of Medpace during the first quarter valued at approximately $31,000. DT Investment Partners LLC acquired a new stake in shares of Medpace during the 2nd quarter worth approximately $41,000. Finally, J.Safra Asset Management Corp lifted its holdings in shares of Medpace by 87.0% in the 1st quarter. J.Safra Asset Management Corp now owns 101 shares of the company’s stock worth $41,000 after purchasing an additional 47 shares during the last quarter. Institutional investors own 77.98% of the company’s stock.

Medpace Stock Performance

Shares of NASDAQ MEDP opened at $365.70 on Monday. Medpace Holdings, Inc. has a 1 year low of $227.21 and a 1 year high of $459.77. The firm has a market cap of $11.33 billion, a P/E ratio of 37.28, a PEG ratio of 1.74 and a beta of 1.35. The stock has a fifty day moving average price of $378.15 and a two-hundred day moving average price of $391.82.

Medpace (NASDAQ:MEDP) last announced its earnings results on Monday, July 22nd. The company reported $2.75 earnings per share for the quarter, beating the consensus estimate of $2.54 by $0.21. Medpace had a return on equity of 55.14% and a net margin of 16.74%. The business had revenue of $528.10 million during the quarter, compared to analysts’ expectations of $528.41 million. During the same quarter last year, the business posted $1.93 earnings per share. The company’s quarterly revenue was up 14.6% on a year-over-year basis. On average, research analysts predict that Medpace Holdings, Inc. will post 11.66 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. Truist Financial initiated coverage on Medpace in a research report on Thursday, August 1st. They issued a “hold” rating and a $415.00 target price on the stock. Deutsche Bank Aktiengesellschaft reduced their target price on shares of Medpace from $395.00 to $336.00 and set a “hold” rating for the company in a research note on Wednesday, July 24th. Mizuho began coverage on shares of Medpace in a research note on Tuesday, May 28th. They issued a “buy” rating and a $435.00 price target on the stock. Guggenheim reduced their price objective on Medpace from $464.00 to $432.00 and set a “buy” rating for the company in a research report on Wednesday, July 24th. Finally, William Blair restated an “outperform” rating on shares of Medpace in a research report on Wednesday, September 11th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, Medpace has a consensus rating of “Moderate Buy” and an average target price of $420.88.

Medpace Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.